JP2017508816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508816A5 JP2017508816A5 JP2017501113A JP2017501113A JP2017508816A5 JP 2017508816 A5 JP2017508816 A5 JP 2017508816A5 JP 2017501113 A JP2017501113 A JP 2017501113A JP 2017501113 A JP2017501113 A JP 2017501113A JP 2017508816 A5 JP2017508816 A5 JP 2017508816A5
- Authority
- JP
- Japan
- Prior art keywords
- heterocyclyl
- heteroaryl
- alkyl
- aralkyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000011780 sodium chloride Substances 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 230000000155 isotopic Effects 0.000 claims 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrugs Drugs 0.000 claims 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- -1 C 7-15 aralkylene Chemical group 0.000 claims 2
- 230000002730 additional Effects 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 claims 1
- 102100010782 EGFR Human genes 0.000 claims 1
- 101700039191 EGFR Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 0 CC(C(C12)=*)=C(*)C(*)=C1N=C(*C(*)=N)N2I** Chemical compound CC(C(C12)=*)=C(*)C(*)=C1N=C(*C(*)=N)N2I** 0.000 description 16
- FJBJSPQFBVVBGM-YFDXKITBSA-N Cc1nccc(C(Nc2nc(ccc3c4[U]CC[U]CCO3)c4[n]2[C@H](CCCC2)CN2C(C=C)=O)=[U])c1 Chemical compound Cc1nccc(C(Nc2nc(ccc3c4[U]CC[U]CCO3)c4[n]2[C@H](CCCC2)CN2C(C=C)=O)=[U])c1 FJBJSPQFBVVBGM-YFDXKITBSA-N 0.000 description 1
- KLPHZWSGEXOTLK-VEIFNGETSA-N Cc1nccc(C(Nc2nc3ccc4OCCNCCOc4c3[n]2[C@H](CCC2)CN2C(C=C)=O)=[U])c1 Chemical compound Cc1nccc(C(Nc2nc3ccc4OCCNCCOc4c3[n]2[C@H](CCC2)CN2C(C=C)=O)=[U])c1 KLPHZWSGEXOTLK-VEIFNGETSA-N 0.000 description 1
Claims (16)
- 式Iの化合物、又はその単一のエナンチオマー、ラセミ混合物、ジアステレオマーの混合物、若しくは同位体変種;又はその医薬として許容し得る塩、溶媒和物、若しくはプロドラッグ:
R2は、C1-6アルキル、C2-6アルケニル、C2-6アルキニル、C3-10シクロアルキル、C6-14アリール、C7-15アラルキル、ヘテロアリール、又はヘテロシクリルであり;
L1は、結合、-O-、-S-、-N(R1A)-、又は-C(R1AR1B)-であり(ここで、各R1A及びR1Bは、独立に、水素、ハロ、C1-6アルキル、C2-6アルケニル、C2-6アルキニル、C3-7シクロアルキル、C6-14アリール、C7-15アラルキル、ヘテロアリール、又はヘテロシクリルである);
L2は、C3-10シクロアルキレン、C6-14アリーレン、C7-15アラルキレン、ヘテロアリーレン、又はヘテロシクリレンであり;
Tは、結合、-O-、-S-、-N=、-N(R4)-、又は-C(R4)=であり;
Uは、結合、-O-、-S-、-N=、-N(R5)-、又は-C(R5)=であり;
Vは、結合、-O-、-S-、-N=、-N(R6)-、又は-C(R6)=であり;
Wは、結合、-O-、-S-、-N=、-N(R7)-、又は-C(R7)=であり;
X及びYは、それぞれ独立に、C又はNであり;
Zは、NR2A又はCR2AR2Bであり(ここで、各R2A及びR2Bは、独立に、水素、ハロ、C1-6アルキル、C2-6アルケニル、C2-6アルキニル、C3-7シクロアルキル、C6-14アリール、C7-15アラルキル、ヘテロアリール、又はヘテロシクリルである);
R4、R5、R6、及びR7は、それぞれ独立に、(a)水素、シアノ、ハロ、若しくはニトロ;(b)C1-6アルキル、C2-6アルケニル、C2-6アルキニル、C3-10シクロアルキル、C6-14アリール、C7-15アラルキル、ヘテロアリール、若しくはヘテロシクリル;又は(c)-C(O)R1a、-C(O)OR1a、-C(O)NR1bR1c、-C(NR1a)NR1bR1c、-OR1a、-OC(O)R1a、-OC(O)OR1a、-OC(O)NR1bR1c、-OC(=NR1a)NR1bR1c、-OS(O)R1a、-OS(O)2R1a、-OS(O)NR1bR1c、-OS(O)2NR1bR1c、-NR1bR1c、-NR1aC(O)R1d、-NR1aC(O)OR1d、-NR1aC(O)NR1bR1c、-NR1aC(=NR1d)NR1bR1c、-NR1aS(O)R1d、-NR1aS(O)2R1d、-NR1aS(O)NR1bR1c、-NR1aS(O)2NR1bR1c、-SR1a、-S(O)R1a、-S(O)2R1a、-S(O)NR1bR1c、若しくは-S(O)2NR1bR1cであり;但し、R4、R5、R6、及びR7の少なくとも2つが水素でないことを条件とし;且つ、R4とR5、R5とR6、又はR6とR7とが結合して、ヘテロアリール又はヘテロシクリルを形成することを条件とし;
各R1a、R1b、R1c、及びR1dは、独立に、水素、C1-6アルキル、C2-6アルケニル、C2-6アルキニル、C3-7シクロアルキル、C6-14アリール、C7-15アラルキル、ヘテロアリール、又はヘテロシクリルであるか;或いは、R1aとR1cとは、それらが結合しているC及びN原子と共に、ヘテロシクリルを形成するか;或いはR1bとR1cとは、それらが結合するN原子と共に、ヘテロシクリルを形成し;且つ
各R1e、R1f、及びR1gは、独立に、水素、ハロ、C1-6アルキル、C2-6アルケニル、C2-6アルキニル、C3-7シクロアルキル、C6-14アリール、C7-15アラルキル、ヘテロアリール、又はヘテロシクリルであり;
但し、T、U、V、及びWの1つ以下が結合であることを条件とし;
ここで、各アルキル、アルケニル、アルキニル、シクロアルキル、シクロアルキレン、アリール、アリーレン、アラルキル、アラルキレン、ヘテロアリール、ヘテロアリーレン、ヘテロシクリル、及びヘテロシクリレンは、1つ以上の置換基Qにより任意に置換されており、ここで、各Qは、(a)オキソ、シアノ、ハロ、及びニトロ;(b)それぞれ、1つ以上の置換基Qaにより任意にさらに置換されている、C1-6アルキル、C2-6アルケニル、C2-6アルキニル、C3-7シクロアルキル、C6-14アリール、C7-15アラルキル、ヘテロアリール、及びヘテロシクリル;並びに、(c)-C(O)Ra、-C(O)ORa、-C(O)NRbRc、-C(NRa)NRbRc、-ORa、-OC(O)Ra、-OC(O)ORa、-OC(O)NRbRc、-OC(=NRa)NRbRc、-OP(O)(ORa)2、-OS(O)Ra、-OS(O)2Ra、-OS(O)NRbRc、-OS(O)2NRbRc、-NRbRc、-NRaC(O)Rd、-NRaC(O)ORd、-NRaC(O)NRbRc、-NRaC(=NRd)NRbRc、-NRaS(O)Rd、-NRaS(O)2Rd、-NRaS(O)NRbRc、-NRaS(O)2NRbRc、-SRa、-S(O)Ra、-S(O)2Ra、-S(O)NRbRc、及び-S(O)2NRbRcから独立に選択され(ここで、各Ra、Rb、Rc、及びRdは、独立に、(i)水素;(ii)それぞれ、1つ以上の置換基Qaにより任意に置換されている、C1-6アルキル、C2-6アルケニル、C2-6アルキニル、C3-7シクロアルキル、C6-14アリール、C7-15アラルキル、ヘテロアリール、又はヘテロシクリルであるか;或いは、(iii)RbとRcとは、それらが結合しているN原子と共に、1つ以上の置換基Qaにより任意に置換されているヘテロシクリルを形成する);
ここで、各Qaは、(a)オキソ、シアノ、ハロ、及びニトロ;(b)C1-6アルキル、C2-6アルケニル、C2-6アルキニル、C3-7シクロアルキル、C6-14アリール、C7-15アラルキル、ヘテロアリール、及びヘテロシクリル;並びに、(c)-C(O)Rf、-C(O)ORf、-C(O)NRgRh、-C(NRf)NRgRh、-ORf、-OC(O)Rf、-OC(O)ORf、-OC(O)NRgRh、-OC(=NRf)NRgRh、-OP(O)(ORf)2、-OS(O)Rf、-OS(O)2Rf、-OS(O)NRgRh、-OS(O)2NRgRh、-NRgRh、-NRfC(O)Rk、-NRfC(O)ORk、-NRfC(O)NRgRh、-NRfC(=NRk)NRgRh、-NRfS(O)Rk、-NRfS(O)2Rk、-NRfS(O)NRgRh、-NRfS(O)2NRgRh、-SRf、-S(O)Rf、-S(O)2Rf、-S(O)NRgRh、及び-S(O)2NRgRhからなる群から独立に選択され;ここで、各Rf、Rg、Rh、及びRkは、独立に、(i)水素;(ii)C1-6アルキル、C2-6アルケニル、C2-6アルキニル、C3-7シクロアルキル、C6-14アリール、C7-15アラルキル、ヘテロアリール、又はヘテロシクリルであるか;或いは、(iii)RgとRhとは、それらが結合しているN原子と共に、ヘテロシクリルを形成する)。 - 式IVの構造を有する、請求項1記載の化合物、又はその単一のエナンチオマー、ラセミ混合物、ジアステレオマーの混合物、若しくは同位体変種;又はその医薬として許容し得る塩、溶媒和物、若しくはプロドラッグ:
nは、0、1、2、3、4、5、又は6の整数であり;
各RLは、独立に、(i)水素;又は(ii)それぞれ、1つ以上の置換基Qにより任意に置換されている、C1-6アルキル、C2-6アルケニル、C2-6アルキニル、C3-10シクロアルキル、C6-14アリール、C7-15アラルキル、ヘテロアリール、若しくはヘテロシクリル;又は(iii)-C(O)R1a、-C(O)OR1a、-C(O)NR1bR1c、-C(NR1a)NR1bR1c、-OR1a、-OC(O)R1a、-OC(O)OR1a、-OC(O)NR1bR1c、-OC(=NR1a)NR1bR1c、-OS(O)R1a、-OS(O)2R1a、-OS(O)NR1bR1c、-OS(O)2NR1bR1c、-NR1bR1c、-NR1aC(O)R1d、-NR1aC(O)OR1d、-NR1aC(O)NR1bR1c、-NR1aC(=NR1d)NR1bR1c、-NR1aS(O)R1d、-NR1aS(O)2R1d、-NR1aS(O)NR1bR1c、-NR1aS(O)2NR1bR1c、-SR1a、-S(O)R1a、-S(O)2R1a、-S(O)NR1bR1c、若しくは-S(O)2NR1bR1cであるか;或いは
同じ環に結合するRLが2つ以上ある場合に、2つのRLは結合して、(i)結合、-O-、-NRN-、若しくは-S-;又は(ii)それぞれ、1つ以上の置換基Qにより任意に置換されている、C1-6アルキレン、C1-6ヘテロアルキレン、C2-6アルケニレン、若しくはC2-6ヘテロアルケニレンを形成し;且つ
RNは(a)水素;(b)それぞれ、1つ以上の置換基Qにより任意に置換されている、C1-6アルキル、C2-6アルケニル、C2-6アルキニル、C3-7シクロアルキル、C6-14アリール、C7-15アラルキル、ヘテロアリール、若しくはヘテロシクリル;(c)-C(O)OR1a、-C(O)NR1bR1c、-C(NR1a)NR1bR1c、-OR1a、-OC(O)R1a、-OC(O)OR1a、-OC(O)NR1bR1c、-OC(=NR1a)NR1bR1c、-OS(O)R1a、-OS(O)2R1a、-OS(O)NR1bR1c、-OS(O)2NR1bR1c、-NR1bR1c、-NR1aC(O)R1d、-NR1aC(O)OR1d、-NR1aC(O)NR1bR1c、-NR1aC(=NR1d)NR1bR1c、-NR1aS(O)R1d、-NR1aS(O)2R1d、-NR1aS(O)NR1bR1c、-NR1aS(O)2NR1bR1c、-S(O)R1a、-S(O)2R1a、-S(O)NR1bR1c、若しくは-S(O)2NR1bR1cである)。 - 請求項1〜13のいずれか一項記載の化合物及び医薬として許容し得る賦形剤を含む医薬組成物。
- ERBB媒介性の病態、障害、又は疾患の1つ以上の症状を治療し、予防し、又は寛解させるための医薬の製造における、請求項1〜13のいずれか一項記載の化合物の使用。
- 増殖性疾患の1つ以上の症状を治療し、予防し、又は寛解させるための医薬の製造における、請求項1〜13のいずれか一項記載の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461968243P | 2014-03-20 | 2014-03-20 | |
US61/968,243 | 2014-03-20 | ||
PCT/US2015/021475 WO2015143161A1 (en) | 2014-03-20 | 2015-03-19 | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017508816A JP2017508816A (ja) | 2017-03-30 |
JP2017508816A5 true JP2017508816A5 (ja) | 2018-05-17 |
JP6568926B2 JP6568926B2 (ja) | 2019-08-28 |
Family
ID=52808184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017501113A Active JP6568926B2 (ja) | 2014-03-20 | 2015-03-19 | 癌の治療のためのerbbチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体 |
Country Status (9)
Country | Link |
---|---|
US (4) | US10202398B2 (ja) |
EP (1) | EP3119784B1 (ja) |
JP (1) | JP6568926B2 (ja) |
KR (1) | KR102409739B1 (ja) |
CN (1) | CN106661027B (ja) |
AU (1) | AU2015231215B2 (ja) |
CA (1) | CA2943231C (ja) |
TW (1) | TWI705967B (ja) |
WO (1) | WO2015143161A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3119762T (pt) * | 2014-03-20 | 2021-08-31 | Capella Therapeutics Inc | Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro |
AU2015231215B2 (en) | 2014-03-20 | 2019-07-18 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
WO2017053537A1 (en) * | 2015-09-23 | 2017-03-30 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
EP3755694B1 (en) | 2018-02-21 | 2023-04-05 | Boehringer Ingelheim International GmbH | New benzimidazole compounds and derivatives as egfr inhibitors |
WO2019227007A1 (en) | 2018-05-25 | 2019-11-28 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
WO2020028566A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
WO2020028565A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Tricyclic heteraryl compounds as sting activators |
US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
WO2020260252A1 (en) | 2019-06-24 | 2020-12-30 | Boehringer Ingelheim International Gmbh | New macrocyclic compounds and derivatives as egfr inhibitors |
CN111855192B (zh) * | 2020-07-31 | 2021-04-23 | 北京航空航天大学 | 一种用于编码器信号去噪的奇异值分解方法 |
EP4237423A1 (en) | 2020-11-02 | 2023-09-06 | Boehringer Ingelheim International GmbH | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
US5958458A (en) | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
EP0835101B1 (en) | 1995-06-27 | 2004-06-09 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
EP1007012A4 (en) | 1996-10-01 | 2006-01-18 | Cima Labs Inc | TASTE-MASKED MICRO-CAPSULE COMPOSITION AND MANUFACTURING PROCESS |
US6375987B1 (en) | 1996-10-01 | 2002-04-23 | Gattefossé, S.A. | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
PT839525E (pt) | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
DE19648576C2 (de) | 1996-11-23 | 1999-08-12 | Lohmann Therapie Syst Lts | Lutschtablette zur modifizierten Freisetzung von Wirkstoffen im Gastrointestinaltrakt |
US6197350B1 (en) | 1996-12-20 | 2001-03-06 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US5990146A (en) * | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US7169410B1 (en) | 1998-05-19 | 2007-01-30 | Sdg, Inc. | Targeted liposomal drug delivery system |
IL142896A0 (en) | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
US6623756B1 (en) | 2000-04-27 | 2003-09-23 | Noveon Ip Holdings Corp. | Directly compressed solid dosage articles |
BR0113626A (pt) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
RU2245136C2 (ru) | 2001-07-27 | 2005-01-27 | Яманоути Фармасьютикал Ко., ЛТД | Композиция, включающая тонкодисперсные частицы с замедленным высвобождением для быстроразлагающихся в щечной полости таблеток, и способ ее получения |
EP1429746B1 (en) | 2001-09-28 | 2008-08-13 | McNEIL-PPC, INC. | Dosage forms having an inner core and outer shell |
CA2458533C (en) * | 2001-10-09 | 2011-01-04 | Tularik Inc. | Imidazole derivates as anti-inflammatory agents |
ATE287259T1 (de) | 2001-12-19 | 2005-02-15 | Astrazeneca Ab | Neue filmbeschichtung enthaltend ein äthylacrylate/methylmethacrylate-copolymer und polyvinylacetat |
US6958161B2 (en) | 2002-04-12 | 2005-10-25 | F H Faulding & Co Limited | Modified release coated drug preparation |
US7485322B2 (en) | 2002-12-24 | 2009-02-03 | Lek Pharmaceuticals D.D. | Modified release pharmaceutical composition |
WO2005105814A1 (en) * | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
US7427414B2 (en) | 2006-01-18 | 2008-09-23 | Astron Research Limited | Modified release oral dosage form using co-polymer of polyvinyl acetate |
US8846697B2 (en) * | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
KR101675614B1 (ko) | 2009-10-29 | 2016-11-11 | 벡투라 리미티드 | Jak3 키나아제 저해제로서의 n―함유 헤테로아릴 유도체 |
BR112012017269A2 (pt) * | 2010-01-12 | 2016-05-03 | Hoffmann La Roche | compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos |
WO2011099832A2 (en) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
JP5795635B2 (ja) | 2010-08-05 | 2015-10-14 | アムジェン インコーポレイテッド | 未分化リンパ腫キナーゼを阻害するベンゾイミダゾール化合物およびアザベンゾイミダゾール化合物 |
MX2014005632A (es) | 2011-11-14 | 2014-10-17 | Tesaro Inc | Modulacion de ciertas cinasas de tirosina. |
CA2854188A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
WO2013153539A1 (en) * | 2012-04-13 | 2013-10-17 | Glenmark Pharmaceuticals S.A. | Tricyclic compounds as tec kinase inhibitors |
US20150099721A1 (en) | 2012-05-10 | 2015-04-09 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
JO3300B1 (ar) * | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
WO2013184766A1 (en) * | 2012-06-06 | 2013-12-12 | Irm Llc | Compounds and compositions for modulating egfr activity |
US9550737B2 (en) | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
AU2013283318B2 (en) | 2012-06-27 | 2017-11-23 | 4Sc Ag | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders |
WO2014036016A1 (en) | 2012-08-31 | 2014-03-06 | Principia Biopharma Inc. | Benzimidazole derivatives as itk inhibitors |
EP3114124A1 (en) | 2014-03-03 | 2017-01-11 | Principia Biopharma, Inc. | BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS |
AU2015231215B2 (en) | 2014-03-20 | 2019-07-18 | Capella Therapeutics, Inc. | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer |
PT3119762T (pt) | 2014-03-20 | 2021-08-31 | Capella Therapeutics Inc | Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro |
CN104447765A (zh) | 2014-12-31 | 2015-03-25 | 深圳铂立健医药有限公司 | 三环化合物及其药物组合物和应用 |
-
2015
- 2015-03-19 AU AU2015231215A patent/AU2015231215B2/en active Active
- 2015-03-19 KR KR1020167028921A patent/KR102409739B1/ko active IP Right Grant
- 2015-03-19 US US15/127,000 patent/US10202398B2/en active Active
- 2015-03-19 JP JP2017501113A patent/JP6568926B2/ja active Active
- 2015-03-19 EP EP15714130.0A patent/EP3119784B1/en active Active
- 2015-03-19 WO PCT/US2015/021475 patent/WO2015143161A1/en active Application Filing
- 2015-03-19 TW TW104108912A patent/TWI705967B/zh active
- 2015-03-19 CA CA2943231A patent/CA2943231C/en active Active
- 2015-03-19 CN CN201580023798.4A patent/CN106661027B/zh active Active
-
2019
- 2019-02-07 US US16/270,470 patent/US10683304B2/en active Active
-
2020
- 2020-06-15 US US16/902,184 patent/US11242352B2/en active Active
-
2021
- 2021-12-20 US US17/556,626 patent/US11713322B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017508816A5 (ja) | ||
JP2017512833A5 (ja) | ||
JP2016510323A5 (ja) | ||
JP2019524883A5 (ja) | ||
JP2017537940A5 (ja) | ||
JP2014509647A5 (ja) | ||
JP2015509535A5 (ja) | ||
JP2012523419A5 (ja) | ||
JP2013533884A5 (ja) | ||
JP2017511815A5 (ja) | ||
JP2015143283A5 (ja) | ||
JP2015528812A5 (ja) | ||
JP2013530236A5 (ja) | ||
AR066904A1 (es) | Pirrolopiridinas y pirazolopiridinas sustituidas como moduladores de las quinasas, una composicion farmaceutica que las incluye y su uso en el tratamiento del cancer | |
JP2012092103A5 (ja) | ||
JP2013528182A5 (ja) | ||
JP2018504437A5 (ja) | ||
CY1118107T1 (el) | Παραγωγα ετεροαρυλιου ως διαμορφωτες αλφα7 nachr | |
JP2013507448A5 (ja) | ||
JP2014518286A5 (ja) | ||
JP2016503052A5 (ja) | ||
JP2015517555A5 (ja) | ||
JP2007531782A5 (ja) | ||
JP2016513130A5 (ja) | ||
JP2018533593A5 (ja) |